Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: progressive metastatic DTC
I · Intervention 중재 / 시술
apatinib at a dose 500 mg per day after F-Fluorodeoxyglucose (F-FDG) PET/CT
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Moreover, beneficial synergistic and complementary effects were shown when apatinib combined with RAI therapy. [CLINICAL TRIAL REGISTRATION] NCT04180007, Registered November 26, 2019.
[PURPOSE] Management of progressive, metastatic radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) has been a great challenge due to its poor prognosis and limited treatment option
APA
Shi L, You Q, et al. (2022). Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).. Endocrine, 78(1), 68-76. https://doi.org/10.1007/s12020-022-03113-9
MLA
Shi L, et al.. "Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).." Endocrine, vol. 78, no. 1, 2022, pp. 68-76.
PMID
35767182 ↗
Abstract 한글 요약
[PURPOSE] Management of progressive, metastatic radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) has been a great challenge due to its poor prognosis and limited treatment options. Recently, apatinib, an orally anti-angiogenic tyrosine kinase inhibitor (TKI) is reported to be useful for treatment of progressive RAIR-DIC. The aim of this study was to evaluate the antitumour effect of apatinib and the combination therapy with radioactive iodine (RAI) in patients with progressive metastatic DTC.
[METHODS] Five patients (all female, mean age 62 ± 8 years, ranged from 51 to 69 years) with distant metastatic DTC (dmDTC) after total thyroidectomy (TTE) and neck lymph node dissection were treated with apatinib at a dose 500 mg per day after F-Fluorodeoxyglucose (F-FDG) PET/CT. The effects of apatinib on DTC were evaluated at 4 ± 1 months after treatment with apatinib. RAI therapy was then initiated. The response to apatinib and the combination therapy with RAI treatment was evaluated by Response Evaluation Criteria in Solid Tumours (RECIST, version 1.1) and metabolic activity using serum thyroglobulin (Tg) and F-FDG PET/CT.
[RESULTS] Positive F-FDG PET/CT results were found in all patients before apatinib therapy. The immunohistochemical analysis of primary tumour tissues showed high expression of vascular endothelial growth factor receptor-2 (VEGFR-2). Four patients with follicular thyroid carcinoma (FTC) showed partial response (PR) with significant decrease in tumour size and maximum standardized uptake value (SUVmax) after 4 ± 1 month's treatment with apatinib. Further significant reduction of tumour size and SUVmax were observed in three patients after combination therapy with apatinib and RAI. Only one patient with both FTC and papillary thyroid cancer (PTC) demonstrated progressive disease (PD) after treatment with apatinib alone, however, a decrease in tumour size and SUVmax as well as serum Tg levels was achieved after the combination with RAI therapy and apatinib.
[CONCLUSIONS] Apatinib had significant antitumour effects on progressive distant metastatic DTC. Moreover, beneficial synergistic and complementary effects were shown when apatinib combined with RAI therapy.
[CLINICAL TRIAL REGISTRATION] NCT04180007, Registered November 26, 2019.
[METHODS] Five patients (all female, mean age 62 ± 8 years, ranged from 51 to 69 years) with distant metastatic DTC (dmDTC) after total thyroidectomy (TTE) and neck lymph node dissection were treated with apatinib at a dose 500 mg per day after F-Fluorodeoxyglucose (F-FDG) PET/CT. The effects of apatinib on DTC were evaluated at 4 ± 1 months after treatment with apatinib. RAI therapy was then initiated. The response to apatinib and the combination therapy with RAI treatment was evaluated by Response Evaluation Criteria in Solid Tumours (RECIST, version 1.1) and metabolic activity using serum thyroglobulin (Tg) and F-FDG PET/CT.
[RESULTS] Positive F-FDG PET/CT results were found in all patients before apatinib therapy. The immunohistochemical analysis of primary tumour tissues showed high expression of vascular endothelial growth factor receptor-2 (VEGFR-2). Four patients with follicular thyroid carcinoma (FTC) showed partial response (PR) with significant decrease in tumour size and maximum standardized uptake value (SUVmax) after 4 ± 1 month's treatment with apatinib. Further significant reduction of tumour size and SUVmax were observed in three patients after combination therapy with apatinib and RAI. Only one patient with both FTC and papillary thyroid cancer (PTC) demonstrated progressive disease (PD) after treatment with apatinib alone, however, a decrease in tumour size and SUVmax as well as serum Tg levels was achieved after the combination with RAI therapy and apatinib.
[CONCLUSIONS] Apatinib had significant antitumour effects on progressive distant metastatic DTC. Moreover, beneficial synergistic and complementary effects were shown when apatinib combined with RAI therapy.
[CLINICAL TRIAL REGISTRATION] NCT04180007, Registered November 26, 2019.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Adenocarcinoma
- Follicular
- Aged
- Female
- Fluorodeoxyglucose F18
- Humans
- Iodine Radioisotopes
- Middle Aged
- Positron Emission Tomography Computed Tomography
- Pyridines
- Thyroglobulin
- Thyroid Neoplasms
- Vascular Endothelial Growth Factor A
- Apatinib
- Metastatic differentiated thyroid cancer
- Radioactive iodine (RAI)
- Tyrosine kinase inhibitor
같은 제1저자의 인용 많은 논문 (5)
- Severe bone resorption in expanded polytetrafluoroethylene chin augmentation.
- Next-generation sequencing for DLBCL patients with early failure after frontline R-CHOP chemo-immunotherapy.
- [Clinical efficacy analysis of seven pediatric patients with Acute myeloid leukemia and the t(16;21)(p11;q22) FUS::ERG fusion gene].
- Halofuginone exerts broad-spectrum cytotoxic effects by regulating p-eIF2α-S100A8/A9-calcium signaling, inhibiting global protein synthesis, and reversing the resistance of idarubicin in acute myeloid leukemia.
- NAD precursor supplementation reverses CD36-mediated lipid accumulation and ferroptosis to restore antitumor function of NK cells in DLBCL.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.